← Back to Search
The Search For Low-penetrance Cancer Susceptibility Alleles
R. Houlston, J. Peto
Published 2004 · Biology, Medicine
Download PDFAnalyze on Scholarcy
Much of the familial aggregation of common cancer results from inherited susceptibility, but highly penetrant mutations in known genes cannot account for most of the excess. Some of the unexplained familial risk is presumably due to high-penetrance mutations in as yet unidentified genes, but polygenic mechanisms are likely to account for a greater proportion, particularly in breast cancer. This inference, coupled with technological developments, has led to a renaissance in association studies. Most such studies have evaluated small numbers of single-nucleotide polymorphisms (SNPs) in a few candidate genes, but reliable high-density oligonucleotide arrays and other novel techniques will allow genome-wide allelic association studies to be conducted. High-density genome-wide SNP analysis will include targets identified by structural considerations, as well as the growing list of candidate genes. In the longer term, high-throughput re-sequencing will be required to identify the rare pathogenic variants that may constitute the majority of low-penetrance alleles. The detection of low-penetrance cancer susceptibility genes will then be restricted mainly by the availability of large numbers of well-characterized cases and controls. Cancer patients with affected relatives are considerably more informative than unselected cases for such studies.
This paper references
J Peto (1996)
AM Dunning (1999)
Point: myeloperoxidase -463G --> a polymorphism and lung cancer risk.
A. Feyler (2002)
Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease.
A. Rostami-Hodjegan (1998)
Linkage of early-onset familial breast cancer to chromosome 17q21.
J. M. Hall (1990)
MM DeMille (2002)
Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland.
P. Lichtenstein (2000)
Genetic mapping of a locus predisposing to human colorectal cancer.
P. Peltomäki (1993)
Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk.
S. Benhamou (2002)
Genetic study of breast cancer: Identification of a high risk group
D. E. Anderson (1974)
A Lindbolm (1993)
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
D. Ford (1998)
NE Morton (2001)
Banbury Report 4: Cancer Incidence In Defined Populations Cairns J, Lyon JL and Skolnick MH (eds) Cold Spring Harbor Laboratories: Cold Spring Harbor, New York, pp
J. Peto (1980)
Polymorphisms and colorectal tumor risk.
R. Houlston (2001)
The optimal measure of allelic association
N. Morton (2001)
Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.
R. Wooster (1994)
MR Stratton (2000)
C Ntais (2003)
Localization of the gene for familial adenomatous polyposis on chromosome 5
W. Bodmer (1987)
A Feyler (2002)
Città DI Torino (1824)
PD Pharoah (2002)
Anglian Breast Cancer Study Group (2000)
JK Pritchard (2000)
RS Houlston (2003)
NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population.
P. Marcus (2000)
Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22.
L. Cannon-Albright (1992)
L. Kruglyak (1999)
A Collins (2001)
SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis.
C. Ntais (2003)
J Peto (2000)
The Future of Genetic Studies of Complex Human Diseases
N. Risch (1996)
D Botstein (2003)
NJ Lench (2000)
M Hedman (1998)
A Weston (1997)
A systematic review of genetic polymorphisms and breast cancer risk.
A. Dunning (1999)
AM Dunning (2000)
Banbury Report 4: Cancer Incidence In Defined Populations
J Peto (1980)
Breast cancer susceptibility-A new look at an old model.
J. Peto (2002)
The extent of linkage disequilibrium in four populations with distinct demographic histories.
A. Dunning (2000)
J Mangion (2002)
AC Antoniou (2003)
Extent and distribution of linkage disequilibrium in three genomic regions.
G. Abecasis (2001)
Association mapping in structured populations.
J. Pritchard (2000)
P Peltomaki (2003)
G. H. Bush (1968)
CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.
D. Easton (2004)
Linkage disequilibrium in the human genome
David E. Reich (2001)
Allelic association with SNPs: Metrics, populations, and the linkage disequilibrium map
A. Collins (2001)
DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis
G. K. Dasika (1999)
This paper is referenced by
Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer
Nigel P. S. Crawford (2005)
MLH1 -93G>A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer.
Stavroula R Raptis (2007)
PTPRJ Haplotypes and Colorectal Cancer Risk
A. Toland (2008)
p53 Genotypes and Risk of Glioma and Meningioma
B. Malmer (2005)
Role of S128R polymorphism of E‐selectin in colon metastasis formation
R. Alessandro (2007)
Nuclear receptor coregulator SNP discovery and impact on breast cancer risk
R. J. Hartmaier (2009)
cancers : actualités et perspectives
D. Stoppa-Lyonnet (2005)
From cellular to high-throughput predictive assays in radiation oncology: challenges and opportunities.
S. Bentzen (2008)
NOD 2 / CARD 15 variants in Malaysian patients with sporadic colorectal cancer
T. P. Lau (2014)
Family history of cancer: Pooled analysis in the International Head and Neck Cancer Epidemiology Consortium
E. Negri (2009)
Influence of Polymorphisms in DNA Repair Genes XPD, XRCC1 and MGMT on DNA Damage Induced by Gamma Radiation and its Repair in Lymphocytes In Vitro
J. Rzeszowska-Wolny (2005)
MSH2 118T>C and MSH6 159C>T promoter polymorphisms and the risk of colorectal cancer.
M. Mrkonjic (2007)
Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer
L. Cavallone (2010)
Association of polymorphisms in transforming growth factor-β receptors with susceptibility to gastric cardia adenocarcinoma
W. Guo (2011)
Use of elderly tumor-free subjects as a “supercontrol” for cancer epidemiological studies: pros and cons
E. Imyanitov (2009)
The HapMap Project and Low-Penetrance Cancer Susceptibility Alleles
Edwin Choy (2010)
Diet, lifestyle, heritable factors and colorectal carcinogenesis: associations with histopathological and molecular endpoints
P. Wark (2007)
The molecular epidemiology of lung cancer.
A. Schwartz (2007)
Genetic Predisposition to Sporadic Cancer: How to Handle Major Effects of Minor Genes?
R. Fijneman (2005)
Cigarette Smoke and Cancer
S. Kachhap (2011)
Association studies in thyroid cancer susceptibility: are we on the right track?
I. Landa (2011)
Variants in the ATM‐CHEK2‐BRCA1 axis determine genetic predisposition and clinical presentation of papillary thyroid carcinoma
A. Wójcicka (2014)
ARLTS1 - a novel tumor suppressor gene.
S. Yendamuri (2008)
CHEK2 1100delC and polygenic susceptibility to breast cancer and colorectal cancer
Marijke Wasielewski (2009)
Common Variants Confer Susceptibility to Barrett's Esophagus: Insights from the First Genome-Wide Association Studies.
C. Palles (2016)
No Evidence of False Reassurance among Women with an Inconclusive BRCA1/2 Genetic Test Result
M. Dorval (2005)
Pancreatic cancer risk variant ABO rs505922 in patients with cholangiocarcinoma.
Marcin Krawczyk (2011)
The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases.
G. De Vecchi (2008)
Population-based family studies: Genetic contribution to cancer development and survival?
L. Lindström (2008)
Genetic Predictors of Clinical Outcomes in Non-Small Cell Lung Cancer Patients
Xia Pu (2012)
Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis.
B. Frank (2008)
Pharmacogenetic screening of docetaxel, irinotecan and fluoropyrimidines in cancer therapy
T. Bosch (2006)See more